Quick Answer
Sunshine Biopharma Inc. reported Cash and Equivalents of $21.83 million for fiscal year 2022.
Sunshine Biopharma Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $21.83M | +967.2% |
| 2021 | $2.05M | +106.6% |
| 2020 | $989.9K | +2344.1% |
| 2019 | $40.5K | -63.4% |
| 2018 | $110.5K | +2.8% |
| 2017 | $107.5K | +87.2% |
| 2016 | $57.5K | +13.1% |
| 2015 | $50.8K | -64.6% |
| 2014 | $143.4K | +359.1% |
| 2013 | $31.2K | -76.4% |
| 2012 | $132.6K | +118.5% |
| 2011 | $60.7K | -62.6% |
| 2010 | $162.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2023 | $19.73M | -52.7% | +2.3% |
| March 31, 2023 | $19.29M | +46.4% | -11.6% |
| December 31, 2022 | $21.83M | +967.2% | -46.2% |
| September 30, 2022 | $40.56M | +1599.3% | -2.8% |
| June 30, 2022 | $41.73M | +2304.9% | +216.7% |
| March 31, 2022 | $13.18M | +633.5% | +544.3% |
| December 31, 2021 | $2.05M | +106.6% | -14.3% |
| September 30, 2021 | $2.39M | +388.4% | +37.5% |
- Sunshine Biopharma Inc. showed an increase of +967.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2022 period, Sunshine Biopharma Inc.’s cash and equivalents has grown by 13340.7% (from $162.4 thousand to $21.83 million).
- The most recent figure is from Sunshine Biopharma Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 4, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: